Olfr61, a member of the olfactory receptor family, plays a pivotal role in the intricate process of olfactory signal transduction within the sensory epithelium. As a G protein-coupled receptor (GPCR), Olfr61 is instrumental in recognizing and transducing signals from specific odorant molecules, initiating downstream events that lead to the perception of olfactory stimuli. Functionally, Olfr61 engages in diverse intracellular pathways, including the Ergosterol biosynthesis, Notch signaling, AMP-activated protein kinase (AMPK), HSP90, PPARγ, sphingosine-1-phosphate receptors, ERK5, PI3K/Akt, endoplasmic reticulum calcium stores, and the MEK/ERK pathway. The inhibition of Olfr61 is orchestrated by a spectrum of chemicals that act through both direct and indirect mechanisms. Clotrimazole, for instance, serves as an indirect inhibitor by targeting the Ergosterol biosynthesis pathway, causing downstream alterations that negatively regulate Olfr61 expression. In parallel, RO4929097 inhibits Olfr61 through specific interference with the Notch signaling pathway, disrupting downstream cascades and negatively affecting Olfr61 function within cellular contexts. These inhibitors collectively underscore the intricate regulatory network governing Olfr61 activity, offering insights into potential strategies for modulating olfactory perception.
Indirect inhibitors, such as FTY720 (Fingolimod) and Wortmannin, modulate sphingosine-1-phosphate receptors and the PI3K/Akt pathway, respectively, leading to downstream alterations that negatively regulate Olfr61 expression and function. Specific interference with the MEK/ERK pathway by PD98059 and disruption of endoplasmic reticulum calcium stores by Thapsigargin illustrate the interconnected nature of olfactory signal transduction pathways. The diverse mechanisms of inhibition highlight the multifaceted nature of olfactory receptor regulation, opening avenues for further exploration into the molecular intricacies of olfactory perception. In summary, Olfr61 serves as a molecular mediator in olfactory signal transduction, with its inhibition governed by a variety of chemicals influencing key cellular pathways associated with its function. The interplay between these inhibitors and the intricate pathways linked to Olfr61 underscores the complexity of olfactory receptor regulation, providing valuable insights into potential strategies for modulating olfactory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole acts as an indirect inhibitor by targeting the Ergosterol biosynthesis pathway. Inhibition of Ergosterol synthesis leads to downstream alterations that negatively regulate Olfr61 expression. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
RO4929097 inhibits Olfr61 through specific interference with the Notch signaling pathway. Its action on Notch disrupts downstream signaling cascades, negatively affecting Olfr61 function within cellular contexts. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Compound C acts as an indirect inhibitor by targeting AMP-activated protein kinase (AMPK). Inhibition of AMPK disrupts downstream signaling cascades, negatively influencing Olfr61 function. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
Tanespimycin serves as a direct inhibitor by targeting HSP90. Inhibition of HSP90 disrupts downstream chaperone activities, negatively impacting Olfr61 function within the cellular context. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 acts as an indirect inhibitor by interfering with peroxisome proliferator-activated receptor-gamma (PPARγ). Its action on PPARγ disrupts downstream events that negatively regulate Olfr61 expression. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
FTY720 inhibits Olfr61 through modulation of sphingosine-1-phosphate receptors. Its impact on sphingosine signaling disrupts downstream cascades, negatively affecting Olfr61 function within cellular contexts. | ||||||
XMD 8-92 (free base) | 1234480-50-2 | sc-364068 sc-364068A sc-364068B sc-364068C | 5 mg 10 mg 100 mg 1 g | $235.00 $340.00 $1700.00 $10330.00 | 10 | |
XMD8-92 inhibits Olfr61 through specific interference with the ERK5 signaling pathway. Its action on ERK5 disrupts downstream signaling cascades, negatively affecting Olfr61 function within cellular contexts. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 serves as an indirect inhibitor by targeting PI3K. Its interference with PI3K disrupts downstream Akt signaling, negatively impacting Olfr61 function within the cellular environment. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits Olfr61 through disruption of the endoplasmic reticulum calcium stores. The altered calcium homeostasis negatively affects Olfr61 signaling and overall cellular impact. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits Olfr61 through specific interference with the MEK/ERK pathway. Its action on MEK disrupts downstream ERK activation, negatively affecting Olfr61 function within cellular contexts. | ||||||